Hyloris Pharmaceuticals SA (ENXTBR:HYL) acquired Global Rights to CRD-102 from Baker Heart and Diabetes Institute on October 8, 2021. The consideration will be paid as upfront payment of AUD 0.05 million to the Baker Institute plus sales-based milestone payments and tiered, single to double digit net profit shares in markets where Hyloris intends to self-commercialize CRD102. In markets where Hyloris intends to seek commercial partnerships, the Baker Institute is eligible to receive tiered, single to double digit net profit shares on net sub-license income. Hyloris Pharmaceuticals SA (ENXTBR:HYL) completed the acquiistion of Global Rights to CRD-102 from Baker Heart and Diabetes Institute on October 8, 2021.